Pfizer stock is poised to release Q2 earnings on Aug. 5, with shares currently trading at $24.23, down from a high of $26.73. Analysts project EPS of $3.01 this year and $3.08 in 2026, indicating potential undervaluation. Historical data suggests a potential upside of +32.6% if stock reverts to average valuation.

Analysts see Pfizer stock as undervalued, with a potential upside of +22.3%. Using historical data, PFE could be worth $32.13 based on P/E, $41.45 based on dividend yield, and $29.65 based on analyst targets. This suggests a potential upside of +42%, though no guarantees exist.

Investors may consider selling OTM put options for extra income while waiting for PFE to reach its potential value. For example, the $23.00 put option offers a 1.13% yield and downside protection. With a breakeven point of $22.74, investors could see an expected return of over 3.3% over the next 3 months.

Overall, Pfizer stock appears deeply undervalued, presenting an opportunity for investors to generate extra income through shorting OTM puts. This strategy could provide a potential upside of over +50% even if the stock falls to $23.00, making it an attractive investment option.

Read more at Yahoo Finance: Pfizer Stock Is a Value Play Ahead of Earnings